Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBEHAVIORAL PHARMACOLOGY

Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3′,5′-Monophosphate-Regulated Phosphoprotein of 32 kDa “Knockout” Mutants Congenic on the C57BL/6 Genetic Background

Rachel E. Nally, Anthony Kinsella, Orna Tighe, David T. Croke, Allen A. Fienberg, Paul Greengard and John L. Waddington
Journal of Pharmacology and Experimental Therapeutics September 2004, 310 (3) 1281-1287; DOI: https://doi.org/10.1124/jpet.104.068957
Rachel E. Nally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Kinsella
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orna Tighe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David T. Croke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allen A. Fienberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Greengard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John L. Waddington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Given the critical role of dopamine- and adenosine 3′,5′-monophosphate-regulated phosphoprotein of 32 kDa (DARPP-32) in the regulation of dopaminergic function, DARPP-32-null mutant mice congenic on the inbred C57BL/6 strain for 10 generations were examined phenotypically for their ethogram of responsivity to the selective D2-like receptor agonist RU 24213 (N-n-propyl-N-phenylethyl-p-3-hydroxyphenylethylamine) and the selective D2-like receptor antagonist YM 09151-2 (cis-N-[1-benzyl-2-methyl-pyrrolidin-3-yl]-5-chloro-2-methoxy-4-methylaminobenzamide), using procedures that resolve all topographies of behavior in the natural repertoire. After vehicle challenge, levels of sniffing and rearing seated were reduced in DARPP-32 mutants; the injection procedure seems to constitute a “stressor” that reveals phenotypic effects of DARPP-32 deletion not apparent under natural conditions. Topographical effects of 0.3 to 10.0 mg/kg RU 24213, primarily induction of sniffing and ponderous locomotion with accompanying reductions in rearing, grooming, sifting and chewing, were not altered to any material extent in DARPP-32-null mice. However, topographical effects of 0.005 to 0.625 mg/kg YM 09151-2, namely, reduction in sniffing, locomotion, rearing, grooming, and chewing but not sifting, were essentially absent in DARPP-32 mutants. Thus, the D2-like receptor agonist-mediated ethogram was essentially conserved, whereas major elements of the corresponding D2-like receptor antagonist-mediated ethogram were essentially absent in DARPP-32-null mice. This suggests some relationship between 1) extent of tonic dopaminergic activation of DARPP-32 mechanisms and 2) compensatory mechanisms consequent to the developmental absence of DARPP-32, which may emerge to act differentially on individual elements of the DARPP-32 system. Critically, the present data indicate that phenotypic effects of a given gene deletion using an agonist acting on the system disrupted cannot be generalized to a corresponding antagonist, and vice versa.

Footnotes

  • This work was supported by Science Foundation Ireland-Enterprise Ireland, the Stanley Medical Research Institute, and a Galen Fellowship from the Irish Brain Research Foundation, in the Institute of Biopharmaceutical Sciences under the Higher Education Authority's Programme for Research in Third Level Institutions (to J.L.W.) and by the Peter Jay Sharp Foundation Grants MH 40899, DA 10044, and MH 39327 (to P.G.).

  • doi:10.1124/jpet.104.068957.

  • ABBREVIATIONS: DARPP-32, dopamine- and adenosine 3′,5′-monophosphate-regulated phosphoprotein of 32 kDa; PP-1, protein phosphatase-1; PKA, protein kinase A; RU 24213, N-n-propyl-N-phenylethyl-p-3-hydroxyphenylethylamine; YM 09151-2, cis-N-[1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-methylaminobenzamide.

    • Received March 26, 2004.
    • Accepted May 12, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 310 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 310, Issue 3
1 Sep 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3′,5′-Monophosphate-Regulated Phosphoprotein of 32 kDa “Knockout” Mutants Congenic on the C57BL/6 Genetic Backg…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBEHAVIORAL PHARMACOLOGY

Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3′,5′-Monophosphate-Regulated Phosphoprotein of 32 kDa “Knockout” Mutants Congenic on the C57BL/6 Genetic Background

Rachel E. Nally, Anthony Kinsella, Orna Tighe, David T. Croke, Allen A. Fienberg, Paul Greengard and John L. Waddington
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1281-1287; DOI: https://doi.org/10.1124/jpet.104.068957

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleBEHAVIORAL PHARMACOLOGY

Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3′,5′-Monophosphate-Regulated Phosphoprotein of 32 kDa “Knockout” Mutants Congenic on the C57BL/6 Genetic Background

Rachel E. Nally, Anthony Kinsella, Orna Tighe, David T. Croke, Allen A. Fienberg, Paul Greengard and John L. Waddington
Journal of Pharmacology and Experimental Therapeutics September 1, 2004, 310 (3) 1281-1287; DOI: https://doi.org/10.1124/jpet.104.068957
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Varenicline and epibatidine as opioid adjuvants
  • MCAM reverses and prevents fentanyl ventilatory depression
  • Kv7 opener SCR2682 alleviates pain
Show more Behavioral Pharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics